Basic information Safety Related Supplier

ChemicalBook Product Catalog Poloxin-2

1/1

Poloxin-2 NEW

$210.00 1mg

$582.00 5mg

$720.00 10mg

Min. Order
Purity99.76%
Cas No321695-37-8
Supply Ability10g
Update time2026-04-13

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP6Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Poloxin-2
CAS No	321695-37-8
EC-No
Min. Order
Purity	99.76%
Supply Ability	10g
Release date	2026/04/13

Product Introduction

Bioactivity

Name	Poloxin-2
Description	Poloxin-2 is a potent and selective Plk1 PBD inhibitor with anti-tumour activity that reduces the protein level of Plk1 in HeLa cells.
In vitro	Poloxin-2 increases neurite differentiation of rat NPCs in a dose-dependent manner (EC50=~1 μM) in adherent culture. Under neural sphere-forming conditions, Poloxin-2 (1.5-5 μM) induces neuronal formation in secondary neurospheres derived from adult rat hippocampus and subventricular zone (SVZ) (40-60% TuJ1+ cells).Furthermore, hippocampal NPCs treated with Poloxin-2and cultured on microelectrode arrays for 12 days exhibit neuronal morphology and spontaneous spike activity, indicating the presence of functional, mature neurons[2].In comparison to cells treated with the carrier (dimethyl sulfoxide, DMSO),Poloxin-2 significantly attenuates the growth of tumor cells.TACC3 is a known target of Poloxin-2 in rodent neural progenitor cells. Poloxin-2 has been shown to induce instability in cells expressing TACC3, leading to a gradual reduction in endogenous TACC3 protein levels over time[1].
In vivo	In tumors treated with Poloxin-2, there is a significant reduction in tumor cell proliferation (approximately two-fold decrease). Compared to tumors treated with the carrier control, Poloxin-2-treated tumors show signs of increased cell death (reduced cell structures/increased condensation). Poloxin-2treatment markedly reduces the expansion of frontal-to-tail tumor growth and corpus callosum invasion in waveform protein-positive GBM1 cells. It was also observed that the survival rate of animals carrying GBMX1 tumors (established 2 or 6 weeks prior to treatment) significantly increases with the 10-week Poloxin-2treatment regimen. No mouse had to be removed from the study due to adverse effects of the treatment. Another experiment using continuous Poloxin-2 treatment until the endpoint also shows a significant increase in the survival rate of animals carrying GBMX1 tumors. Histopathological endpoint analysis of animals treated with Poloxin-2 and the vehicle confirms a significant reduction in tumor size in Poloxin-2-treated mice[1].
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMSO : 12.5 mg/mL (46.42 mM), Sonication is recommended.
Keywords	Poloxin-2 \| PLK1
Inhibitors Related	TTK/PLK1-IN-1 \| T521 \| (E/Z)-Rigosertib sodium \| Cyclapolin 9 \| SBE13 Hydrochloride \| Pyridoxine \| Rigosertib sodium \| 3MB-PP1 \| Ro3280 \| Volasertib \| BI 2536 \| GSK461364
Related Compound Libraries	Bioactive Compound Library \| Kinase Inhibitor Library \| Post-Translational Modification Compound Library \| Inhibitor Library \| Bioactive Compounds Library Max \| Cell Cycle Compound Library \| Anti-Cancer Compound Library \| Anti-Cancer Active Compound Library

show more

Company Profile Introduction

You may like

Recommended supplier

Send Inquriy